Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

(2021) Apostolia‐Maria Tsimberidou et al.   ONCOLOGIST

Nivolumab for the salvage treatment of desperate germ cell tumor: A case report

(2020) MS Aksun et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

(2019) M. Mego et al.   INVESTIGATIONAL NEW DRUGS

Utility of the Quasi-monomorphic Variation Range in Unresectable Metastatic Colorectal Cancer Patients

(2018) Hideaki Bando et al.   CANCER SCIENCE

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

(2018) Andrea Necchi et al.   EUROPEAN UROLOGY

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

(2018) Xian Shen et al.   BMJ-British Medical Journal

Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation

(2017) Stefanie Zschäbitz et al.   EUROPEAN JOURNAL OF CANCER

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors

(2016) S. Zschäbitz et al.   ANNALS OF ONCOLOGY

Platinum-refractory germ cell tumors: an update on current treatment options and developments

(2016) Christoph Oing et al.   WORLD JOURNAL OF UROLOGY

Absence of microsatellite instability andBRAF(V600E) mutation in testicular germ cell tumors

(2016) F. M. Cárcano et al.   Andrology

Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors

(2016) S. Shah et al.   Cancer Immunology Research

Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors

(2015) Z. Cierna et al.   ANNALS OF ONCOLOGY

Frequent PD-L1 expression in testicular germ cell tumors

(2015) C D Fankhauser et al.   BRITISH JOURNAL OF CANCER

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Testicular Cancer — Discoveries and Updates

(2014) Nasser H. Hanna et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

(2011) Darren R. Feldman et al.   CANCER

Histopathological and molecular features of late relapses in non-seminomas

(2010) Frank Mayer et al.   BJU INTERNATIONAL

Regression of metastatic seminoma in a patient referred for carcinoma of unknown primary origin

(2010) John E. Musser et al.   Nature Reviews Urology

Microsatellite Instability, Mismatch Repair Deficiency, andBRAFMutation in Treatment-Resistant Germ Cell Tumors

(2009) Friedemann Honecker et al.   JOURNAL OF CLINICAL ONCOLOGY